Skip to main content
. 2023 May 3;77(2):214–221. doi: 10.1097/MPG.0000000000003816

TABLE 1.

Patient characteristics

Study population Group A (n = 8) Group B (n = 7) P values
(n = 15) Start exercise Start control Group A vs B
Female, n (%) 6 (40) 3 (37.5) 3 (43) 0.85
Age, y 15 [12 to 16] 15.5 [14.3 to 16.0] 12 [9 to 15] 0.07
Age at diagnosis, y 9.5 (4.0) 10.9 (4.2) 7.9 (3.3) 0.15
Height for age, SDS −0.23 [−1.95 to 0.7] −0.19 [−0.98 to 0.65] −0.65 [−0.95 to 0.7] 1.00
Weight for height, SDS 0.95 [0.1 to 3.19] 1.52 [0.37 to 3.39] 0.21 [−0.38 to 0.95] 0.04 *
BMI, kg/m 2 20.4 [17.5 to 31.5] 24.0 [18.5 to 32.4] 17.5 [16.3 to 22.3] 0.07
Disease type (%)
 Ulcerative colitis 5 (33.3) 1 (12.5) 4 (57) 0.07
 Crohn disease 10 (66.7) 7 (87.5) 3 (43)
Extra intestinal manifestation (%)
 Arthralgia/arthritis 3 (20) 2 (25) 1 (14.3)
 Primary sclerosing cholangitis 2 (13) 1 (12.5) 1 (14.3)
 Active perianal fistulae 1 (6.7) 1 (12.5) 0
COVID-19 positive during study (%) 1 (6.7) 0 1 (14.3)
PCDAI + PUCAI 15 [2.5 to 22.5] 10 [0.63 to 20.6] 15 [5 to 30] 0.08
Maintenance treatment, n (%)
 Aminosalicylates 4 (26.6) 3 (37.5) 1 (12.5)
 Immunomodulators 10 (66.7) 4 (50) 6 (85.7)
 Biologicals 10 (66.7) 5 (62.5) 5 (71.4)
 Corticosteroids 0 0 01
 No medication 0 0 0

Values are shown in mean ± SD or as median [IQR]. P values were measured using paired t testing (parametric data) or Wilcoxon rank sum test (nonparametric data). Difference between Group A and B were calculated using the Chi-square test or Fisher exact test. 1: One patient in group B received prednisolone during the exercise intervention, Supplement 2, Supplemental Digital Content, http://links.lww.com/MPG/D157 shows detailed medication descriptions including doses.

BMI = body weight index; PCDAI = Pediatric Crohn Disease Activity Index; PUCAI = Pediatric Ulcerative Colitis Activity Index; SDS = standard deviation score; vs = versus.

*

P < 0.05.